Maula Eka Sriyani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Maula Eka Sriyani has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Eva Maria Widyasari
School of Pharmacy, Bandung Institute of Technology, Bandung, Indonesia
3 shared publications - Ahmad Kurniawan
National Nuclear Energy Agency
2 shared publications - Danni Ramdhani
Department of Pharmaceutical Analysis and Medicinal Chemistry, Faculty of Pharmacy, Universitas Padjadjaran, Jl Ir. Soekarno KM 21, Jatinangor 45363, Indonesia
2 shared publications - Hendris Wongso
Research Center for Radioisotope, Radiopharmaceutical, and Biodosimetry Technology, National Research and Innovation Agency, Bandung, Indonesia
2 shared publications - Isa Mahendra
Research Center for Radioisotope, Radiopharmaceuticals and Biodosimetry Technology, National Research and Innovation Agency, Serpong, Indonesia
2 shared publications - Isti Daruwati
National Nuclear Energy Agency
2 shared publications
Latest Publications
- Open Access
Preclinical Evaluation of Chicken Egg Yolk Antibody (IgY) Anti-RBD Spike SARS-CoV-2—A Candidate for Passive Immunization against COVID-19
The coronavirus disease 2019 (COVID-19) has become a substantial threat to the international health sector and the global economy. As of 26 December 2021, the number of mortalities resulting from COVID-19 exceeded 5.3 million worldwide. The absence of an effective non-vaccine treatment has prompted the quest for prophylactic agents that can be used to combat COVID-19. This study presents the feasibility of chicken egg yolk antibody (IgY) anti-receptor-binding domain (RBD) spike SARS-CoV-2 as a strong candidate to neutralize the virus for application in passive immunization. For the purpose of preclinical studies, we radiolabeled IgY anti-RBD spike SARS-CoV-2 with radionuclide iodine-131. This allowed us to evaluate several biological characteristics of IgY in vitro, in vivo, and ex vivo. The preclinical data suggest that IgY anti-RBD spike SARS-CoV-2 could specifically bind to the SARS-CoV-2 antigens; however, little uptake was observed in normal cells (MRC-5) (<2%). Furthermore, the ex vivo biodistribution study revealed that IgY predominantly accumulated in the trachea of normal mice compared to other organs. We also found that IgY possessed a good safety profile when used as an intranasal agent. Taken together, we propose that IgY anti-RBD spike SARS-CoV-2 has the potential for application in passive immunization against COVID-19.
Open AccessPreclinical Evaluation of Chicken Egg Yolk Antibody (IgY) Anti-RBD Spike SARS-CoV-2—A Candidate for Passive Immunization against COVID-19
The coronavirus disease 2019 (COVID-19) has become a substantial threat to the international health sector and the global economy. As of 26 December 2021, the number of mortalities resulting from COVID-19 exceeded 5.3 million worldwide. The absence of an effective non-vaccine treatment has prompted the quest for prophylactic agents that can be used to combat COVID-19. This study presents the feasibility of chicken egg yolk antibody (IgY) anti-receptor-binding domain (RBD) spike SARS-CoV-2 as a strong candidate to neutralize the virus for application in passive immunization. For the purpose of preclinical studies, we radiolabeled IgY anti-RBD spike SARS-CoV-2 with radionuclide iodine-131. This allowed us to evaluate several biological characteristics of IgY in vitro, in vivo, and ex vivo. The preclinical data suggest that IgY anti-RBD spike SARS-CoV-2 could specifically bind to the SARS-CoV-2 antigens; however, little uptake was observed in normal cells (MRC-5) (<2%). Furthermore, the ex vivo biodistribution study revealed that IgY predominantly accumulated in the trachea of normal mice compared to other organs. We also found that IgY possessed a good safety profile when used as an intranasal agent. Taken together, we propose that IgY anti-RBD spike SARS-CoV-2 has the potential for application in passive immunization against COVID-19.
- Open Access
- 6 April 2016
- Published by National Research and Innovation Agency in Atom Indonesia
- Vol. 42 (1) , 27-32
Profile of MIBI Liquid Phase Radiopharmaceutical for Myocardial Imaging
Profile of MIBI Liquid Phase Radiopharmaceutical for Myocardial Imaging
- 6 April 2016
- Published by National Research and Innovation Agency in Atom Indonesia
- Vol. 42 (1) , 27-32
Open AccessProfile of MIBI Liquid Phase Radiopharmaceutical for Myocardial Imaging
Profile of MIBI Liquid Phase Radiopharmaceutical for Myocardial Imaging
- Open Access
- 1 January 2015
- Published by Elsevier in Procedia Chemistry
- Vol. 16, 245-250
Iodination Method of Quercetin for Synthesis of Anticancer Labelled Compound
- 1 January 2015
- Published by Elsevier in Procedia Chemistry
- Vol. 16, 245-250
Open AccessIodination Method of Quercetin for Synthesis of Anticancer Labelled Compound
- Open Access
- 3 October 2013
- Published by National Research and Innovation Agency in Atom Indonesia
- Vol. 39 (2) , 82
Physicochemical and Biological Analysis of 99mTc-Glutathione Radiopharmaceuticals
99mTc-glutation (99mTc-GSH) radiopharmaceutical is available in the GSH lyophilized-kit in which ready to use directly after adding 99mTc radionuclide. In nuclear medicine, 99mTc-GSH diagnostic kit is a radiopharmaceutical commonly utilized for cancer diagnoses using imaging method. This paper described the physicochemical and biological characteristics as well as the quality of 99mTc-GSH diagnostic kit prepared from the GSH lyophilized-kit. The radiochemical purity was determined with thin layer chromatography (TLC) method, performed on a TLC-SG stationary phase with a mobile phase of a dried acetone and 0,9% of NaCl solution. Studies on the effect of volume and radioactivity of Na99mTcO4 solution to the radiochemical purity of 99mTc-GSH were carried out. The sterility of GSH-lyophilized kit and toxicity of 99mTc-GSH were also investigated. The stability test on GSH lyophilized kit and 99mTc-GSH in several storage conditions, as well as the plasma stability of 99mTc-GSH was performed. The analysis result showed that the GSH lyophilized-kit was sterile; the 99mTc-GSH was non toxic with 99.54 ± 0.01% of radiochemical purity and remained stable 5 hours either at room temperature or 4 oC. The volume more than 4 mL of Na99mTcO4 solution on the labeling of GSH could decreased the 99mTc-GSH radiochemical purity, while the radioactivity more than 20 mCi in 7 mL of volume extended the incubation time. In-vitro stability test of 99mTc-GSH in plasma showed that in the two hours of storage, the radiochemical purity decreased to 51.84 ± 2.52%, and until 5 hours of storage it did not change significantly. From the result, it can be concluded that the GSH lyophilized-kit was remained stable after 13 month of storage either at room temperature or at 4 oC with 99% of 99mTc-GSH radiochemical purity. Received: 16 January 2013; Revised: 23 August 2013; Accepted: 24 August 2013
- 3 October 2013
- Published by National Research and Innovation Agency in Atom Indonesia
- Vol. 39 (2) , 82
Open AccessPhysicochemical and Biological Analysis of 99mTc-Glutathione Radiopharmaceuticals
99mTc-glutation (99mTc-GSH) radiopharmaceutical is available in the GSH lyophilized-kit in which ready to use directly after adding 99mTc radionuclide. In nuclear medicine, 99mTc-GSH diagnostic kit is a radiopharmaceutical commonly utilized for cancer diagnoses using imaging method. This paper described the physicochemical and biological characteristics as well as the quality of 99mTc-GSH diagnostic kit prepared from the GSH lyophilized-kit. The radiochemical purity was determined with thin layer chromatography (TLC) method, performed on a TLC-SG stationary phase with a mobile phase of a dried acetone and 0,9% of NaCl solution. Studies on the effect of volume and radioactivity of Na99mTcO4 solution to the radiochemical purity of 99mTc-GSH were carried out. The sterility of GSH-lyophilized kit and toxicity of 99mTc-GSH were also investigated. The stability test on GSH lyophilized kit and 99mTc-GSH in several storage conditions, as well as the plasma stability of 99mTc-GSH was performed. The analysis result showed that the GSH lyophilized-kit was sterile; the 99mTc-GSH was non toxic with 99.54 ± 0.01% of radiochemical purity and remained stable 5 hours either at room temperature or 4 oC. The volume more than 4 mL of Na99mTcO4 solution on the labeling of GSH could decreased the 99mTc-GSH radiochemical purity, while the radioactivity more than 20 mCi in 7 mL of volume extended the incubation time. In-vitro stability test of 99mTc-GSH in plasma showed that in the two hours of storage, the radiochemical purity decreased to 51.84 ± 2.52%, and until 5 hours of storage it did not change significantly. From the result, it can be concluded that the GSH lyophilized-kit was remained stable after 13 month of storage either at room temperature or at 4 oC with 99% of 99mTc-GSH radiochemical purity. Received: 16 January 2013; Revised: 23 August 2013; Accepted: 24 August 2013